Literature DB >> 15011959

The recognition of abnormal forms of HLA-B27 by CD4+ T cells.

Louise H Boyle1, Jane C Goodall, J S Hill Gaston.   

Abstract

The MHC class I molecule, HLA-B27 can be expressed as a number of non-conventional forms, in addition to conventional HLA-B27 heterodimers presenting peptide. This has lead to new avenues of research to explain the association of this molecule with SpA. Surprisingly, HLA-B27 transgenic animal models implicated CD4+ T cells, which conventionally interact with MHC class II molecules, not MHC class I molecules, in the pathogenesis of SpA. One hypothesis to explain these finding is that non-conventional forms of HLA-B27, specifically HLA-B27 homodimers, might mimic MHC class II molecules and be recognised by CD4+ T cells. We investigated whether CD4+ T cells from AS patients can interact with HLA-B27, discovering that indeed CD4+ T cells can interact with various forms of HLA-B27. Here we discuss how such interactions between HLA-B27 and CD4+ T cells could occur in vivo and potential contributions of such interactions to the pathogenesis of SpA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15011959     DOI: 10.2174/1566524043479257

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  6 in total

1.  High-affinity human leucocyte antigen class I binding variola-derived peptides induce CD4+ T cell responses more than 30 years post-vaccinia virus vaccination.

Authors:  M Wang; S T Tang; O Lund; M H Dziegiel; S Buus; M H Claesson
Journal:  Clin Exp Immunol       Date:  2009-03       Impact factor: 4.330

2.  Inverse correlation of programmed death 1 (PD-1) expression in T cells to the spinal radiologic changes in Taiwanese patients with ankylosing spondylitis.

Authors:  Ming-Han Chen; Wei-Sheng Chen; Hui-Ting Lee; Chang-Youh Tsai; Chung-Tei Chou
Journal:  Clin Rheumatol       Date:  2011-03-10       Impact factor: 2.980

3.  T-cell responses to versican in ankylosing spondylitis.

Authors:  Tae-Jong Kim; Tae-Hwan Kim; Hyun-Joo Lee; Bitnara Lee; A Robin Poole; Robert D Inman
Journal:  Rheumatol Int       Date:  2009-12-11       Impact factor: 2.631

4.  Association between C-reactive protein gene variant and treatment efficacy of etanercept in ankylosing spondylitis patients receiving hip arthroplasty.

Authors:  Yuansheng Xu; Wei Jiang; Hui Zhang
Journal:  J Clin Lab Anal       Date:  2020-04-20       Impact factor: 2.352

Review 5.  The Potential Role of Genetics, Environmental Factors, and Gut Dysbiosis in the Aberrant Non-Coding RNA Expression to Mediate Inflammation and Osteoclastogenic/Osteogenic Differentiation in Ankylosing Spondylitis.

Authors:  Hsien-Tzung Liao; Chang-Youh Tsai; Chien-Chih Lai; Song-Chou Hsieh; Yi-Syuan Sun; Ko-Jen Li; Chieh-Yu Shen; Cheng-Han Wu; Cheng-Hsun Lu; Yu-Min Kuo; Tzu-Hao Li; Chung-Tei Chou; Chia-Li Yu
Journal:  Front Cell Dev Biol       Date:  2022-01-20

6.  The genetic association of RUNX3 with ankylosing spondylitis can be explained by allele-specific effects on IRF4 recruitment that alter gene expression.

Authors:  Matteo Vecellio; Amity R Roberts; Carla J Cohen; Adrian Cortes; Julian C Knight; Paul Bowness; B Paul Wordsworth
Journal:  Ann Rheum Dis       Date:  2015-10-09       Impact factor: 19.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.